Morgan Stanley Call 128 6MK 20.12.../ DE000ME2ESB7 /
28/08/2024 18:34:24 | Chg.+0.052 | Bid22:00:35 | Ask22:00:35 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.226EUR | +29.89% | - Bid Size: - |
- Ask Size: - |
MERCK CO. D... | 128.00 - | 20/12/2024 | Call |
GlobeNewswire
17/07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
09/07
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination ...
GlobeNewswire
25/06
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
06/03
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...